Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 298

Sort by

Sort Order Select

Journal Articles

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

Yanyan Shao, Wenman Wu, Guanqun Xu, Xuefeng Wang, Qiulan Ding

Blood (2019) 134 (20): 1745–1754.

https://doi.org/10.1182/blood.2018886069

Published: 2019

Includes: Supplemental data

Journal Articles

Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholestrolemia

Bryce Kerlin, Amanda P. Waller, PhD, Jonathan P. Troost, PhD, Samir Parikh, MD, William E. Smoyer, MD, Matthias Kretzler, MD

Blood (2019) 134 (Supplement_1): 2422.

https://doi.org/10.1182/blood-2019-128680

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Blood (2019) 134 (Supplement_1): 610.

https://doi.org/10.1182/blood-2019-125968

Published: 2019

Journal Articles

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Mayken Visser, Rene van Oerle, Hugo ten Cate, MD PhD, Volker Laux, PhD, Stefan Heitmeier, PhD, Henri M.H. Spronk, PhD

Blood (2019) 134 (Supplement_1): 1106.

https://doi.org/10.1182/blood-2019-131738

Published: 2019

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Siret Tahk, Saskia Schmitt, Christian Peter Augsberger, Binje Vick, PhD, Laia Pascual Ponce, PhD, Irmela Jeremias, MD PhD, Georg Wittmann, MD, Nadja Fenn, PhD, Marion Subklewe, MD, Karl-Peter Hopfner, PhD

Blood (2019) 134 (Supplement_1): 2544.

https://doi.org/10.1182/blood-2019-128145

Published: 2019

Journal Articles

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Megha Ramappan, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 2670.

https://doi.org/10.1182/blood-2019-131949

Published: 2019

Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD

Blood (2019) 134 (Supplement_1): 1869.

https://doi.org/10.1182/blood-2019-121805

Published: 2019

Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3936.

https://doi.org/10.1182/blood-2019-131759

Published: 2019

Journal Articles

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Daisuke Kaji, MD, Manabu Kusakabe, MD PhD, Mamiko Sakata-Yanagimoto, MD PhD, Yasuhito Suehara, MD, Keiichiro Hattori, MD PhD, Yasunori Ota, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 4128.

https://doi.org/10.1182/blood-2019-127521

Published: 2019

Journal Articles

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

Monika Herrmann, Christina Krupka, Katrin Deiser, Bettina Brauchle, Anetta Marcinek, Ana Ogrinc Wagner, Felicitas Rataj, Ralph Mocikat, Klaus H. Metzeler, Karsten Spiekermann, Sebastian Kobold, Nadja C. Fenn, Karl-Peter Hopfner, Marion Subklewe

Blood (2018) 132 (23): 2484–2494.

https://doi.org/10.1182/blood-2018-05-849802

Published: 2018

Includes: Supplemental data

Journal Articles

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

Kenichi Ogiwara, MD PhD, Keiji Nogami, MDPhD, Tomoko Matsumoto, PhD, Mariko Noguchi-Sasaki, PhD, Tetsuhiro Soeda, PhD, Naoki Matsumoto, PhD, Michinori Hirata, PhD, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2018-99-118504

Published: 2018

Journal Articles

A Novel Full Length Anti-FLT3 CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia

Ivana Djuretic, PhD, Veena Krishnamoorthy, PhD, Cesar Sommer, PhD, Danielle E. Dettling, Kris Poulsen, Wei Chen, PhD, Wenyue Hu, PhD, Allison Given Chunyk, Kevin Lindquist, Shobha Potluri, PhD, Robert C Rickert, PhD, Barbra Sasu, PhD, Javier Chaparro-Riggers, PhD, Yik Andy Yeung, PhD

Blood (2018) 132 (Supplement 1): 1445.

https://doi.org/10.1182/blood-2018-99-119915

Published: 2018

Journal Articles

CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format

Yumin CUI, PhD, Zhihua Huang, MSc, Xinfeng Zhang, PhD, Wuzhong Shen, MSc, Hanyang Chen, PhD, Zaiqing Wen, PhD, Bo Qi, MSc, Lan Luo, MSc, Ying Tan, Yun Wu, PhD, Ada Kung, PhD, Xiaoqiang Yan, PhD

Blood (2018) 132 (Supplement 1): 4169.

https://doi.org/10.1182/blood-2018-99-112819

Published: 2018

Journal Articles

A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma

Alexander M. Lesokhin, MD, Noopur Raje, MD, Cristina J Gasparetto, MD, Justine Walker, MD, Heike I. Krupka, PhD PMP, Tenshang Joh, PhD, Carrie T. Taylor, PhD MHS, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2018-99-110427

Published: 2018

Journal Articles

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

Kenichi Ogiwara, MD PhD, Hiroki Horiuchi, Keiji Nogami, MD PhD, Takehisa Kitazawa, DVM, Midori Shima, MD PhD

Blood (2018) 132 (Supplement 1): 2478.

https://doi.org/10.1182/blood-2018-99-118379

Published: 2018

Journal Articles

Decreased Factor V Ameliorates Bleeding Diathesis in Patients with Combined Deficiency of Factor V and Factor VIII

Yanyan Shao, PhD, Wenman WU, MD PhD, Guanqun Xu, B.S, Wang Xuefeng, Ding Qiulan

Blood (2018) 132 (Supplement 1): 2503.

https://doi.org/10.1182/blood-2018-99-118350

Published: 2018

Journal Articles

The Tissue Factor Pathway Inhibitor Antibody, PF-06741086, Increases Thrombin Generation in Rare Bleeding Disorder and Von Willebrand Factor Deficient Plasmas

Swapnil Rakhe, MS, Sunita R. Patel-Hett, PhD, Sheryl Bowley, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2018) 132 (Supplement 1): 2462.

https://doi.org/10.1182/blood-2018-99-119674

Published: 2018

Journal Articles

A Neutralizing Monoclonal Antibody (PF-06741086) Against Tissue Factor Pathway Inhibitor in Combination with Activated Prothrombin Complex Concentrate Increases Hemostasis in Inhibitor Hemophilia Plasmas without Excessive Thrombin Generation

Swapnil Rakhe, MS, Sheryl Bowley, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2018) 132 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2018-99-119831

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholestrolemia

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

A Single Dose of CD117 Antibody Drug Conjugate Enables Autologous Gene-Modified Hematopoietic Stem Cell Transplant (Gene Therapy) in Nonhuman Primates

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Evaluation of a Bifunctional Sirpα-CD123 Fusion Antibody for the Elimination of Acute Myeloid Leukemia Stem Cells

Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Clinicopathological Analysis of "Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders" Reveals a Favorable Outcome Independent of the Effectiveness of Methotrexate Discontinuation in Autoimmune Disease Patients

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia

A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab

A Novel Full Length Anti-FLT3 CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia

CD3-Activating Bi-Specific Antibody Targeting CD19 on B Cells in Mono- and Bi-Valent Format

A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma

Assessment of Emicizumab-Driven Clot Stability in Hemophilia a Model

Decreased Factor V Ameliorates Bleeding Diathesis in Patients with Combined Deficiency of Factor V and Factor VIII

The Tissue Factor Pathway Inhibitor Antibody, PF-06741086, Increases Thrombin Generation in Rare Bleeding Disorder and Von Willebrand Factor Deficient Plasmas

A Neutralizing Monoclonal Antibody (PF-06741086) Against Tissue Factor Pathway Inhibitor in Combination with Activated Prothrombin Complex Concentrate Increases Hemostasis in Inhibitor Hemophilia Plasmas without Excessive Thrombin Generation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only